Ask My Investor AI
Public company · NYSEPublished company research
RMD

Identity verified against ResMed Inc.'s Q3 FY2026 Form 10-Q, CIK 0000943819.

ResMed Inc.

ResMed sells home-based sleep and breathing devices, masks and related software. Q3 FY2026 net revenue was $1,431.4 million, up 11%; Sleep and Breathing Health contributed $1,260.5 million and Residential Care Software $170.9 million. The recurring masks-and-other category grew 15% to $524.8 million.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
RMD
Exchange
NYSE
HQ
United States
Currency
USD
SEC CIK
0000943819
Investment case

How this company captures the theme economics

Competitive position

Official reporting shows scale across devices, masks and care software, with Q3 FY2026 Sleep and Breathing Health revenue up 11% and gross margin at 62.2%. The filing supports product-category performance, not a market-share conclusion.

Scarce assets

The relevant assets are its installed respiratory-device base, recurring mask and accessory demand, connected-care capability, and residential-care software. The source packet does not independently value those assets or establish a competitive moat.

Products, segments, and customers

ResMed reports Sleep and Breathing Health and Residential Care Software. Q3 FY2026 device revenue was $735.7 million, masks and other revenue $524.8 million, and Residential Care Software revenue $170.9 million.

Theme capture

Respiratory devices and recurring supplies are used in home care, while Residential Care Software serves home and hospice, home medical equipment, senior living and long-term care workflows. ResMed does not disclose Aging in Place revenue or age-specific revenue.

Conditions

What must be true

  1. Home-based device and resupply demand continues to grow without material reimbursement or price compression.
  2. The portion of revenue attributable to older adults or aging at home is established through acceptable evidence before the relationship is accepted.

Identifiable catalysts

  • Continued device and mask unit demand
  • Growth in Home and Hospice and Home Medical Equipment software verticals
  • Future official reporting on connected-care adoption and reimbursement
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Home respiratory devices, recurring masks and supplies, and software used across home medical equipment and residential-care workflows.

Aging-in-place economy

Q3 FY2026 Sleep and Breathing Health revenue was $1,260.5 million and Residential Care Software revenue was $170.9 million. Filing commentary identifies Home and Hospice, Home Medical Equipment, Senior Living and Long-Term Care software verticals, establishing a direct home/residential-care operating link but not an aging-specific revenue share.

Evidence
The SEC filing directly supports product, segment and current-period financial claims. It does not quantify revenue from older adults or the Aging in Place theme.
Materiality
estimated — Home and residential-care products are disclosed and financially material; aging-specific attribution remains unreported and requires human review.
Financial evidence

Official SEC filing evidence

Reference period: Q3 FY2026.

  • Net revenue$1,431.4 million; +11% reported
    Q3 FY2026[1]
  • Sleep and Breathing Health revenue$1,260.5 million; +11%
    Q3 FY2026[1]
  • Devices revenue$735.7 million; +9%
    Q3 FY2026[1]
  • Masks and other revenue$524.8 million; +15%
    Q3 FY2026[1]
  • Residential Care Software revenue$170.9 million; +6%
    Q3 FY2026[1]
  • Gross profit and margin$891.0 million; 62.2%
    Q3 FY2026[1]

Limitation: Current results establish operating scale but do not quantify aging-specific revenue. Licensed market valuation is unavailable.

Risks

Material risks and break conditions

Material risks

  • Reimbursement, pricing or patient-adherence changes reduce device or recurring mask demand.
  • Currency movements obscure underlying international growth.
  • Residential Care Software growth weakens in Senior Living and Long-Term Care or fails to offset implementation and operating costs.

Thesis-break conditions

  • Device and masks-and-other revenue contract for multiple reporting periods.
  • Official evidence no longer supports a meaningful home or residential-care operating link.
Investability conclusion

Where the evidence lands

ResMed has a current, filing-backed home and residential-care operating link, but Aging in Place attribution and valuation remain unquantified. The subject remains NOT_READY pending human review.

Next diligence

  1. Quantify resupply economics and reimbursement sensitivity from official sources.
  2. Establish an acceptable age or at-home-care attribution method without inferring unsupported revenue.
  3. Obtain licensed market data and independent human review.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. ResMed Inc. Q3 FY2026 Form 10-QU.S. Securities and Exchange Commission (EDGAR) · primary · published 2026-04-30 · accessed 2026-07-29